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INTRODUCTION 
Carcinoid tumours are rare, but are the most common 
gastrointestinal neuroendocrine tumours. We review 
the diagnosis, pathology and management of goblet 
cell carcinoid of the appendix using an illustrative 
case history.
ILLUSTRATIVE CASE HISTORY
A  21-year-old  man  was  admitted  with  a  24-
hour history of right iliac fossa abdominal pain 
associated with nausea and vomiting. There was 
no  history  of  diarrhoea  or  weight  loss,  and  no 
family history of inflammatory bowel disease. He 
described a one-year history of right iliac fossa 
pain, colicky in nature, lasting for three to four 
days at a time and recurring every three months. 
This was his second hospital admission, the first 
episode settling with conservative management. On 
retrospective questioning he denied any symptoms 
suggestive of carcinoid syndrome.
On  examination  he  was  apyrexic  with  rebound 
tenderness  in  the  right  iliac  fossa.  Blood 
investigations  revealed  a  white  cell  count  of 
19.3x109/L and a C-reactive protein of 260mg/L. 
Abdominal sonography was performed in view of 
the recurrent nature of the pain and the possibility 
of Crohn’s disease. This showed multiple fluid filled 
loops of bowel in the right iliac fossa but no direct 
visualisation  of  the  appendix  and  no  thickened 
loops  of  small  bowel.  Following  a  short  period 
of observation we proceeded to appendicectomy, 
which  confirmed  an  acutely  inflamed  appendix 
with purulent free fluid in the pelvis. There were 
no post-operative complications.
Histopathology  confirmed  acute  appendicitis. 
In addition, within the tip of the appendix there 
was a 4mm tumour composed of small glandular 
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focally  granular  cytoplasm  (figs  1  and  2).  The 
tumour extended through the muscularis propria 
of the appendix into serosal fat, reaching 1.5mm 
from the serosal surface. The tumour was positive 
with  the  epithelial  markers  CAM  5.2,  CEA 
and  neuroendocrine  marker  Neurone  Specific 
Enolase. The tumour cells failed to stain with the 
neuroendocrine marker Chromogranin. Overall the 
histological  and  immunohistochemical  features 
were those of a goblet cell carcinoid tumour of the 
appendix tip with co-existing acute appendicitis.
Post-operatively a plasma neuroendocrine profile, 
including  plasma  Chromogranin A,  and  urinary 
levels  of  5-hydroxyindoleacetic  acid  (5-HIAA) 
and  5-hydroxytrptyphan  (5-HT)  were  within 
normal limits. A CT scan of abdomen and pelvis 
and an octreotide radioisotope scan did not reveal 
any metastatic disease (Fig 3). Despite our patient 
having a tumour size of less than 1 cm, it was felt 
that in view of the presence of mesoappendiceal 
extension  and  his  younger  than  average  age  at 
presentation, a right hemicolectomy was justified 
to decrease his risk of delayed local and distant 
recurrence,  and  to  study  the  regional  lymph 
nodes.  He  proceeded  to  a  laparoscopic  right 
hemicolectomy,  the  pathology  of  which  did  not 
reveal any residual disease and at twelve month 
follow up he remains disease free.
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Fig 1.  Haematoxylin-eosin slide showing tumour infiltrating wall (dark arrow) and a serosal reaction (white arrow).
Fig 2.  Haematoxylin-eosin slide showing tumour cells infiltrating through the muscularis propria (black arrow).©  The Ulster Medical Society, 2006.
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EPIDEMIOLOGY
Carcinoid  tumours  are  rare,  but  are  the  most 
common  neuroendocrine  tumours.1, 2  In  a  series 
of 13,715 carcinoids reported to the Surveillance, 
Epidemiology,  and  End  Results  programme  of 
the National Cancer Institute, the majority were 
located in the gastrointestinal tract (67.5%) and in 
the bronchopulmonary system (25.3%).3 Carcinoid 
tumours are the most common neoplasms arising 
in  the  appendix,  accounting  for  about  85  per 
cent of all appendiceal tumours seen in surgical 
pathology. The prevalence of appendiceal carcinoid 
is between 0.3% and 0.9% in patients undergoing 
appendicectomy. The  recent  study  of  McCusker 
et al,4 reported 227 goblet cell carcinoids (13.8%) 
among 1645 appendiceal malignancies, along with 
613 cases (37%) of mucinous adenocarcinoma, the 
most  frequent  diagnosis.  These  epidemiological 
studies  suggest  an  average  diagnostic  age  of 
between 38 and 49 years for malignant lesions, 
although goblet cell carcinoids tend to present at a 
later age of about 52 years.
Data from the Northern Ireland Neuroendocrine 
Database (Table I) includes 517 carcinoid tumours 
Fig 3. The normal octreotide scan of the patient looking for evidence of metastatic disease. Normal uptake is seen in the liver, 
kidneys and spleen, 24 and 48 hours post injection of radioisotope.
of the appendix, midgut and lung diagnosed since 
1975. 114 of these were appendiceal carcinoids, 
16 of which were goblet cell in nature. The age at 
diagnosis and the presence of metastatic disease is 
shown in the table below. The mean age at diagnosis 
was 54.75 years ±4.57 SEM. Four of the 16 patients 
have  since  died.  The  only  patient  with  hepatic 
metastases died from recurrent goblet cell carcinoid 
tumour, ten years following her appendicectomy 
and subsequent right hemicolectomy.
MALIGNANT CHANGE
Tumour characteristics of all appendiceal carcinoids 
that predict aggressive behaviour include tumour 
size,  histological  subtype  and  mesoappendiceal 
involvement. Moertel et al  5 first indicated in 1968 
that metastatic disease from lesions smaller than 
2cm  was  unlikely  and  consequently  considered 
that  the  risk  of  metastatic  disease  in  tumours 
less  than  2  cm  was  sufficiently  low  to  treat 
them  by  appendicectomy  alone.  In  one  study 
mesoappendiceal extension correlated with nodal 
metastases  and  tumour  size.6  In  a  series  of  92 
appendiceal carcinoids they reported two patients 
with  1cm  tumours  with  nodal  spread,  both  of 
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Table  I
Patients diagnosed with appendiceal carcinoid from the Northern Ireland Neuroendocrine Database
  Patient  Age at Diagnosis  Metastases
  1  78  No
  2  73  Yes - mesentery
  3  39  No
  4  56  No
  5  62  Yes - small bowel
  6  46  No
  7  15  No
  8  65  No
  9  22  No
  10  74  No
  11  59  No
  12  60  No
  13  47  No
  14  67  Yes - hepatic
  15  43  No
  16  70  No©  The Ulster Medical Society, 2006.
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which had mesoappendiceal involvement. Serosal 
involvement is present in about 70% of malignant 
carcinoid tumours but this has been shown to be 
unrelated to outcome in several studies.
DIAGNOSIS
The  diagnosis  of  goblet  cell  carcinoid  of  the 
appendix  is  essentially  made  on  histological 
examination  after  surgery,  which  is  one  of  the 
clinical  hallmarks  of  appendiceal  carcinoids. 
This  neoplasm  has  also  been  described  as  an 
adenocarcinoid, crypt cell carcinoma and goblet 
cell  carcinoma. The  preferred  term,  goblet  cell 
carcinoma, was first coined in 1974 by Subbuswamy 
et al.7 As the nomenclature implies, these tumours 
possess  morphological  features  suggestive  of 
both  carcinoid  and  glandular  differentiation. 
Appendiceal  carcinoids  are  usually  divided  into 
three histological patterns; the typical argentaffin 
enterochromaffin  (EC)-cell  carcinoid,  the  non-
argentaffin L-cell carcinoid and the more recently 
described  goblet  cell  carcinoid. The  goblet  cell 
carcinoids show striking differences in histology 
from the other two varieties but more importantly, 
they are biologically more aggressive lesions.8
Goblet cell carcinoids behave differently biologically 
and their outcome is similarly different. In the study 
by McCusker et al  4 only 17% of 227 patients with 
goblet cell carcinoma had positive lymph nodes, 
but in 65% there was spread through the serosa, 
invasion of the mesoappendix, or involvement of 
peritoneum or adjacent organs. Serosal involvement 
and mesoappendiceal extension are therefore more 
predictive  of  outcome  than  lymph  node  status 
in  goblet  cell  carcinoids.  In  the  Surveillance, 
Epidemiology, and End Results programme of the 
National Cancer Institute, patients with malignant 
carcinoid had a better overall survival rate of more 
than 80% at 10 years compared with goblet cell 
carcinoids which had a 60% 10 year survival rate. 
The survival rate for goblet cell carcinomas was 
not  significantly  worse  than  that  for  malignant 
carcinoid  when  adjusted  for  age  and  extent  of 
disease at presentation.4
INVESTIGATION
Most patients do not require any further procedure 
or  investigations  relating  to  an  appendiceal 
carcinoid. Those patients with tumours larger than 
2cm,  incomplete  resections,  metastatic  disease 
or  goblet  cell  carcinoids  require  estimation  of 
plasma Chromogranin A concentration and 24-hour 
urinary levels of 5-hydroxyindolacetic acid along 
with  CT  scanning  and  octreotide  scintigraphy. 
111 In-labelled octreotide scintigraphy is the most 
sensitive imaging modality in the diagnosis and 
staging of metastatic disease. The isotope scans 
are performed more than eight weeks after initial 
surgery to avoid false positives and therefore any 
unnecessary further surgery.9
Chromogranin A is a secretory protein present in 
vesicles of neuroendocrine cells and its ubiquitous 
presence in these cell types makes it a suitable 
circulating marker of neuroendocrine neoplasms, 
the levels being raised in 80-100% of patients with 
these neoplasms.10 It is currently the most important 
blood marker available for carcinoid tumours, with 
levels  corresponding  to  tumour  load  and  levels 
above 5000 µg/l predicting a poor outcome.11
PROGNOSIS AND
SURGICAL MANAGEMENT
Patients with appendiceal carcinoids have a good 
prognosis overall with the vast majority cured by 
Table  II 
Indications for right hemicolectomy
  1.  All lesions larger than 2cm in diameter 
  2.  Histological evidence of mesoappendiceal extension 
  3.  Tumours at the base of the appendix with positive margins or involvement of the caecum 
  4.  High-grade malignant carcinoids
  5.  Goblet cell carcinoids.13
www.ums.ac.uk©  The Ulster Medical Society, 2006.
Goblet Cell Carcinoids of the Appendix 45
www.ums.ac.uk
simple appendicectomy as the definitive procedure. 
In at least 70% of the cases encountered by most 
general  surgeons,  patients  with  a  tumour  less 
than  1  cm  will  almost  certainly  have  no  future 
problem from the lesion. Patients with goblet cell 
carcinoid  tumours  however  fall  into  a  different 
category,  as  these  tumours  are  more  aggressive 
than  classic  appendiceal  carcinoids.  They  are 
characterized  histologically  by  wide  invasion 
of  the  mesoappendix,  and  clinically  by  delayed 
local  recurrence  and  distant  metastases. As  the 
vast majority of these tumours are detected post-
operatively, management centres on the need for 
re-operation  as  a  right  hemicolectomy  is  often 
curative.12 In patients with goblet cell carcinoids 
relative indications that may favour further surgery 
are: (1) angioinvasion as an isolated finding, (2) 
tumours  at  the  base  of  the  appendix  with  clear 
margins, greater than 1cm but less than 2cm in 
diameter and (3) mucin-producing tumours.13
CONCLUSIONS
When  considering  appendiceal  carcinoids  as 
a  whole,  acceptable  indications  for  a  right 
hemicolectomy  are  shown  in  Table  II.  Careful 
diagnosis and management of goblet cell carcinoid 
tumours  will  hopefully  improve  prognosis  in 
patients with this rare entity.
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